Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Treatment of Opioid Use Disorder: Waiver Qualifying - Marquette, MI - Thursday, May 28, 2020

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live In-Person Event on 05/28/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Thursday, May 28, 2020 |8:00 am - 5:00 pm

    Upper Peninsula Health Plan
    853 West Washington Street
    Marquette, Michigan 49855

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Please park in the UPHP parking lot (off of main entrance). Additional parking along the front of Staybridge Suites (avoid parking at mBank). Upon arrival, please register at reception and a UPHG representative will meet you and take you to the conference room located on the second floor.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Alta DeRoo, MD, FASAM

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Muskegon, MI - Monday, March 2, 2020

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live In-Person Event on 03/02/2020 at 8:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: MICCSI

    Monday, March 2, 2020 | 8:00 am - 5:00 pm

    Muskegon Community College
    Stevenson Center Room 2318
    221 S. Quaterline Road
    Muskegon, MI 49442

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    1. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Alta DeRoo, MD, FASAM

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Kalamazoo, MI - Friday, February 7, 2020

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live In-Person Event on 02/07/2020 at 8:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: MICCSI

    Friday, February 7, 2020 | 8:00 am - 5:00 pm

    Delta Hotels by Marriott
    2747 South 11th Street
    Kalamazoo, MI 49009

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    1. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Alta DeRoo, MD, FASAM

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - New Orleans, LA - Friday, January 31, 2020

    Product not yet rated Contains 7 Component(s), Includes Credits Includes Multiple Live Events. The next is on 01/31/2020 at 9:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: AmeriHealth Caritas

    Friday, January 31, 2020 | 8:00 am - 12:30 pm CT

    AmeriHealth Caritas Louisiana Community Wellness Center
    3155 Gentilly Boulevard
    New Orleans, LA 70122

    Cost: $199
    FREE for ACLA providers
    Limited to prescribers only

    Overview 

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.


    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartNone

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. After the live course, fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion CME Evaluation”.  Tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Locate the box on the right that says “View Course" and click “View Course". A new window will open with the course. Be sure your pop-up blocker is turned off.
    4. Complete Module 1 and Module 2 (equivalent to four hours of instruction). You will be required to pass all CME Quizzes with a grade of 70% or higher.
    5. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Online Portion CME Evaluation”.  Tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window
    6. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    7. Click the button “Claim Medical Credits” in the box titled “Download CME Certificate”.
    8. Choose the type of credit (Physician or Non-physician) and click submit
    9. Click the button “View/Print Certificate” to save or print your certificate. Tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - East Lansing, MI - Friday, January 31, 2020

    Contains 3 Component(s), Includes Credits Includes a Live In-Person Event on 01/31/2020 at 8:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: MICCSI

    Friday, January 31, 2020 | 8:00 am - 5:00 pm

    MSU Breslin Student Events Center
    Meeting Rooms B+C
    534 Birch Road
    East Lansing, MI 48824

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    1. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Alta DeRoo, MD, FASAM

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Elkridge, MD - Thursday, January 23, 2020

    Product not yet rated Contains 6 Component(s), Includes Credits Includes a Live In-Person Event on 01/23/2020 at 8:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: Maryland Patient Safety Center

    Thursday, January 23, 2020  | 8:00 am - 12:30 pm

    Maryland Patient Safety Center
    6820 Deerpath Road
    Elkridge, MD 21075

    Cost: $25

    Online Portion Due: Wednesday, January 22, 2020

    Overview 

    The ASAM Treatment of Opioid Use Disorder Course covers all medications and treatments for opioid use disorder and provides 8 hours of required education needed to obtain the waiver to prescribe buprenorphine. This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's healthcare providers. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder



    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - New Hudson, MI - Monday, January 20, 2020

    Product not yet rated Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 01/20/2020 at 8:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Monday, January 20, 2020 | 8:00 am - 5:00 pm

    Lyon Meadows Conference Center
    53200 Grand River Ave
    New Hudson, MI 48165

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAMNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received? Stock 
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVS None
    Tricia E. Wright, MD, MS, FACOG, DFASAM None


    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD (Chair)None
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRONone
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Sandy MetcalfeNone


    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartNone

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - St. Louis, MO Friday, January 17, 2020

    Product not yet rated Contains 5 Component(s), Includes Credits Includes a Live Web Event on 01/17/2020 at 2:00 PM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        


     image        

     


    Friday, January 17, 2020 | 2:00 pm ET - 6:15 pm ET

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    In the content section you will find 2 different components for the live learning. For those attending live in-person, you can skip over the live webinar portion to complete the CME Evaluation and claim your CME Certificate. 

    For those attending Live-Via Webinar, you will have access to the "Live Webinar" component 30 minutes before the training. You will click on this link to access the webinar on the 29th.

    Getting started: To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."

     If you have any questions, please contact education@ASAM.org.

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module 1 and Module 2 (equivalent to four hours of instruction)
    3. You will be required to pass all CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the two online modules and four hours of live, in-person instruction, you will be able to claim CME credit through the ASAM e-Learning Center




    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Alta DeRoo, MD, D

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Alta DeRoo

    MD, FACOG, FASAM

    Dr. Alta DeRoo has been an attending physician at Naval Medical Center San Diego, Walter Reed National Military Medical Center, Naval Hospital Camp Lejeune and University of Virginia School of Medicine.  She is currently the director of OBGYN at University of Virginia – Culpeper and an associate professor at the University of Virginia School of Medicine.

     

    Dr. DeRoo is board certified by the American Board of Addiction Medicine (ABAM), as well as by the American Board of Obstetrics and Gynecology.   She is a contributor to publications regarding opioid use disorders among pregnant women and lectures frequently on addiction medicine topics.

     

    Dr. DeRoo specializes in treating pregnant women with opioid use disorders and leads an Office Based Opioid Treatment program (OBOT) in Culpeper, VA.  She is the regional clinical champion for the education of physicians regarding buprenorphine waiver training for the state of Virginia.  She is also the secretary for the Virginia Chapter of the American Society of Addiction Medicine.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Champaign, IL - Friday, December 13, 2019

    Contains 6 Component(s), Includes Credits Includes a Live In-Person Event on 12/13/2019 at 8:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: ILPQC

    Friday, December 13, 2019 | 8:00 am - 12:30 pm

    Carle at the Fields
    Champaign, IL
    Cost: $25

    Online Portion Due: Thursday, December 12, 2019

    Overview 

    The ASAM Treatment of Opioid Use Disorder Course covers all medications and treatments for opioid use disorder and provides 8 hours of required education needed to obtain the waiver to prescribe buprenorphine. This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's healthcare providers. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder



    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • ASAM Criteria Course - Salisbury, MD - Monday, December 2, 2019

    Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 12/02/2019 at 8:00 AM (EST)

    The ASAM Criteria Course is a practical workshop designed to help counselors, social workers, administrators, and other clinical staff develop patient-centered service plans and make objective decisions about patient admission, continuing care, and transfer/discharge for individuals with addictive, substance-related, and co-occurring conditions.


    image


    Monday, December 2, 2019 

    8:00 am - 5:00 pm 

    Hampton Inn Salisbury
    121 E. Naylor Mill Road
    Salisbury, MD 21801
    Alvin Snyder Room 

    Overview

    The ASAM Criteria Course will comprise of a comprehensive suite of competency-based learning activities that meets the learning needs of the multiple audiences making use of the Criteria and results in the appropriate use of the Criteria in practice. The ASAM Criteria Course can also serve as a bridge to the implementation of a provider credentialing program. Providers who have completed ASAM approved training on The ASAM Criteria can gain the initial skill set to deliver care in compliance with The ASAM Criteria.

    Getting Started 

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    1. Describe the underlying principles and concepts of the ASAM Criteria.
    2. Identify the six dimensions of the ASAM Criteria’s multidimensional patient assessment.
    3. Determine treatment priorities based on risk assessment to guide treatment and service planning.
    4. Determine an appropriate level of care and treatment priorities based on risk assessment.
    5. Implement the ASAM Criteria, in the context of system challenges, for patients with addiction to ensure appropriate level of care and treatment outcomes.

    Anika Alvanzo

    MD, MS, FASAM, FACP

    Anika Alvanzo, MD, MS is an Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine where she is also the Medical Director of the Johns Hopkins Hospital Substance Use Disorders Consultation Service (SUDS). Dr. Alvanzo is a graduate of the George Washington University School of Medicine and Health Sciences and holds a master's degree in biostatistics from Virginia Commonwealth University. She is board certified in both Internal Medicine and Addiction Medicine. As the Director of the SUDS, Dr. Alvanzo oversees a multidisciplinary consultation service that performs brief behavioral interventions and counseling for hospitalized patients, facilitates linkage to hospital and community-based alcohol and drug treatment programs, provides guidance on the clinical management of substance withdrawal syndromes, and educates patients, families, healthcare professionals and the community to prevent, identify, and treat persons living with addiction. Dr. Alvanzo is also the Director of the Substance Use Disorders Rotation for the Johns Hopkins Medicine-Pediatrics Urban Health and Urban Health Primary Care Residency track programs. Her research interests include gender and race/ethnicity differences in the risk for substance use disorders, integration of technology for screening, brief intervention and referral to treatment in diverse settings and the association between psychological trauma, traumatic stress, and substance use. In particular, she is interested in the mechanisms by which histories of physical and/or sexual violence confer increased risk for substance use disorders and in the development of interventions for co-occurring traumatic stress and substance misuse in women.

    Christine R. Mulford

    RN, MSN, FNP-BC

    Christine brings her more than 15 years of clinical and leadership experience as a Nurse Practitioner to the practice of addiction medicine. She is passionate about individualized patient care as well as community education to end the stigma of substance use and mental health issues.

    Together with her physician partner, she started the first Emergency Room based
    withdrawal management service in the greater Phoenix area. Additionally, she maintains a private addiction medicine practice in Scottsdale, Arizona. Christine received her Master’s Degree in Nursing from Vanderbilt University where she was the 1998 Julia Hereford Merit Scholar. She resides in Phoenix, Arizona with her 2 sometimes well-behaved dogs. She enjoys live music, sports, and trying new hot sauces.